

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2014

PART - I						(Rs. in Lacs)			
	PARTICULARS	STANDALONE							
		QUARTER ENDED			YEAR ENDED				
		30.06.2014 (UNAUDITED)	31.03.2014 (AUDITED)*	30.06.2013 (UNAUDITED)	31.03.2014 (AUDITED)				
1	Income From Operations								
	(a) Net Sales (Net of Excise Duty)	6,980.88	5,373.14	7,371.75	28,349.25				
	(b) Other Operating Income	106.11	175.84	185.92	696.43				
	<b>Total Income From Operations (Net)</b>	<b>7,086.99</b>	<b>5,548.98</b>	<b>7,557.67</b>	<b>29,045.68</b>				
2	<b>Expenses</b>								
	a) Consumption of Raw Materials	2,606.90	2,969.99	3,422.63	13,517.82				
	b) Purchase of Traded Goods	-	529.50	159.46	1,030.40				
	c) (Increase)/Decrease in Stock in Trade	268.11	(369.38)	506.64	60.57				
	d) Employee Benefit Expenses	394.18	340.48	292.91	1,292.61				
	e) Depreciation / Amortisation	112.93	71.57	104.97	446.16				
	f) Other Expenditure	1,672.76	1,363.94	1,854.93	6,314.46				
	<b>Total Expenses</b>	<b>5,054.88</b>	<b>4,906.10</b>	<b>6,341.54</b>	<b>22,662.02</b>				
3	Profit from Operations before other Income & Finance Cost & Exceptional Items (1-2)	2,032.11	642.88	1,216.13	6,383.66				
4	Other Income	249.88	90.01	1,617.56	2,789.81				
5	Profit From Ordinary Activities Before Finance Cost (3+4)	2,281.99	732.89	2,833.69	9,173.47				
6	Finance Cost	223.97	309.44	188.71	943.63				
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,058.02	423.45	2,644.98	8,229.84				
8	Exceptional Items	-	-	-	-				
9	<b>Profit From Ordinary Activities Before Tax (7 - 8)</b>	<b>2,058.02</b>	<b>423.45</b>	<b>2,644.98</b>	<b>8,229.84</b>				
10	Tax Expense (Including Deferred Tax)	658.57	272.00	819.94	2,837.19				
11	<b>Net Profit From Ordinary Activities After Tax (9 - 10)</b>	<b>1,399.45</b>	<b>151.45</b>	<b>1,825.04</b>	<b>5,392.65</b>				
12	Extra Ordinary Items (net of Tax Expenses)	-	-	-	-				
13	<b>Net Profit For The Period (11 - 12)</b>	<b>1,399.45</b>	<b>151.45</b>	<b>1,825.04</b>	<b>5,392.65</b>				
14	Paid - Up Equity Capital	1,031.47	1,031.47	1,031.47	1,031.47				
15	Reserves Excluding Revaluation Reserve (As per Balance Sheet)				30,452.64				
16	<b>Basic And Diluted Eps (Not Annualised)</b>	<b>1.36</b>	<b>0.15</b>	<b>1.77</b>	<b>5.23</b>				
<b>PART - II</b>									
<b>A</b>	<b>Particulars of Shareholding</b>								
1	Aggregate of Non-Promoter Shareholding								
	- No. of Shares (Face Value Rs.1/- Each)	36156842	36156842	36156842	36156842				
	- Percentage of Shareholding (%)	35.05	35.05	35.05	35.05				
2	Promoter and Promoter Group Shareholding								
	A) Pledge/ Encumbered								
	- No. of Shares (Face Value Re.1/- Each)		-	-					
	- Percentage of Shares (As % of the total share Holding of Promoter & Promoter Group)		-	-					
	- Percentage of Shares (As % of the total share Capital of the Company)		-	-					
	B) Non - Encumbered								
	- No. of Shares (Face Value Re.1/- Each)	66989830	66958830	66958830	66959830				
	- Percentage of Shares (As % of the total share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00				
	- Percentage of Shares (As % of the total Share Capital of the Company)	64.95	64.95	64.95	64.95				
	<b>PARTICULARS</b>	<b>Quarter Ended 30, June 2014</b>							
<b>B</b>	<b>INVESTOR COMPLAINTS</b>								
	Pending at the beginning of the quarter			-					
	Received during the quarter			1					
	Disposed off during the quarter			1					
	REMAINING UNSOLVED AT THE END OF THE QUARTER			-					
<b>Notes:-</b>									
1. The Company operates primarily in the pharmaceutical business and hence has only one reportable segment.									
2. The Statutory Auditors have carried out "Limited Review" of the aforesaid results.									
3. The above results were reviewed by the Audit Committee & were there after approved by The Board at its meeting held on August 11, 2014.									
4. During the quarter the Company commenced new manufacturing plant at Palghar, Maharashtra, for enhancement of the existing capacity.									
5. Pursuant to the Companies Act 2013, becoming effective from April 1, 2014, the Company has computed the depreciation based on the useful life of the assets as prescribed in schedule II of the Act. This has resulted in additional charge of depreciation of Rs. 36.25 Lacs for the Quarter Ended June 30, 2014. Further, as per transitional provisions of the Act, the Company has adjusted the written down value of Rs. 4.67 Lacs (Net of Deferred Tax of Rs. 2.39 Lacs) in respect of assets whose residual life is nil as of April 1, 2014 in the opening balance of retained earnings.									
*6. The figures for the Quarter Ended March 31, 2014 are the balancing figures between the Audited figures in respect of the full financial year ended March 31, 2014 and the published year to date figures up to the third Quarter Ended December 31, 2013									
7. Figures for the Previous Year / Quarters have been Regrouped/Rearranged wherever necessary.									

FOR BLISS GVS PHARMA LIMITED

SD/-

S. N. KAMATH  
MANAGING DIRECTOR

Place : Mumbai  
Date : 11-08-2014